A retrospective case-control hospital based study on the diagnostic utility of anti-cyclic citrullinated peptide antibodies in comparison with rheumatoid factor, C-reactive protein and erythrocyte sedimentation rate as a diagnostic inflammatory biomarker
Abstract
Introduction: Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease, characterised by persistent joint inflammation resulting in joint damage and disability. Diagnosis of RA is primarily on clinical manifestations and radiological findings due to lack of reliable diagnostic tests. As substantial joint damage occurs before patient presents clinically, a validated biomarker is required forits early detection.
Objectives: To compare diagnostic utility of laboratory variables like anti–cyclic citrullinated peptide(Anti-CCP) antibodies, Rheumatoid factor (RF), C-reactive protein (CRP)and Erythrocyte sedimentation rate(ESR)in patients with Rheumatoid arthritis(RA).
Materials and Methods: Blood from 80 clinically suspected RA patients and 80 age and sex matched healthy controls were tested for Anti-CCP antibodies, RF, CRP and ESR. Diagnostic properties of Anti-CCP in comparison with RF, CRP and ESR were statistically analysed and p value<0.05 was considered significant.
Results: Anti-CCP was 100% positive in test group and 100% negative in control group with p value <0.001. Correlation between Anti-CCP and RF and Anti CCP and CRP showed significant titres with p value <0.001. Anti-CCP was 100% sensitive and 80% specific compared to RF.
Conclusion: Anti-CCP is more sensitive and specific than other tests available for diagnosis of RA. Combined detection of all four parameters is valuable in confirming diagnosis of RA. Recognition of utility of such biomarkers is essential to gain insight into activity of this disease, which is vital for early management to limit consequential morbidity and to improve quality of life.
Downloads
References
2. Kashyap B, Tiwari U, Garg A, Kaur IR. Diagnostic utility of anti CCP antibodies and rheumatoid factor as inflammatory biomarkers in comparison with C- reactive protein and TNF-α in rheumatoid arthritis. Trop J Med Res 2015;18(1):5-9. DOI: 10.4103/1119-0388.152534
3. Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31 (3): 315-24. DOI: https://doi.org /10.1002/ art. 1780310302
4. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham III CO, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62(9): 2569-81. DOI: 10.1002/art.27584.
5. Banal F, Dougados M, Combescure C, Gossec L. Sensitivity and specificity of the American College of Rheumatology 1987 criteria for the diagnosis of rheumatoid arthritis according to disease duration: a systematic literature review and meta-analysis. Ann Rheum Dis. 2009;68 (7):1184-91. DOI: 10.1136/ ard.2008.093187. Epub 2008 Aug 26.
6. Visser H. Early diagnosis of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2005;19(1):55-72.DOI:10.1016/j.berh. 2004.08.005
7. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2006;65(7):845-51. Epub 2006 Apr 10. DOI: http://dx.doi.org/10.1136/ ard. 2006.051391
8. Masson-Bessière C, Sebbag M, Durieux JJ, et al. In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol. 2000; 119 (3): 544-52.DOI:10.1046/ j.1365-2249.2000.01171.x
9. Rantapää‐Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48 (10):2741-9. DOI: https://doi.org/10.1002/art.11223
10. Vallbracht I, Helmke K. Additional diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Autoimmun Rev. 2005;4(6):389-94. Epub 2005 Mar 9.
11. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358 (9285): 903-11. DOI:10.1016/S0140-6736(01)06075-5
12. Shen R, Ren X, Jing R, Shen X, Chen J, Ju S, et al. Rheumatoid Factor, Anti-Cyclic Citrullinated Peptide Antibody, C-Reactive Protein, and Erythrocyte Sedimentation Rate for the Clinical Diagnosis of Rheumatoid Arthritis. Lab Med. 2015 Summer;46(3): 226-9. DOI: 10.1309/LMZYTSO5RHIHV93T.
13. Kim HH, Kim J, Park SH, Kim SK, Kim OD, Choe JY. Correlation of anti-cyclic citrullinated antibody with hand joint erosion score in rheumatoid arthritis patients. Korean J Intern Med. 2010;25(2):201-6. DOI: 10.3904 / kjim. 2010. 25.2.201. Epub 2010 Jun 1.
14. Al-Shukaili A, Al-Ghafri S, Al-Marhoobi S, Alkaabi J. Evaluation of anti-mutated citrullinated vimentin antibodies, anti-cyclic citrullinated Peptide antibodies and rheumatoid factor in omani patients with rheumatoid arthritis. Int J Rheumatol. 2012; 2012: 285854. DOI: 10.1155/ 2012/ 285854. Epub 2012 Aug 15.
15. García-Berrocal B, González C, Pérez M, Navajo JA, Moreta I, Dávila C, et al. Anticyclic citrullinated peptide autoantibodies in IgM rheumatoid factor-positive patients.ClinChim Acta.2005;354(1-2):123-130. DOI: 10.1016/j. cccn.2004.11.025
16. van Schaardenburg D, Nielen MM, Lems WF, Twisk JW, Reesink HW, van de Stadt RJ et al. Bone metabolism is altered in preclinical rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):1173-4. DOI: 10.1136/ ard.2010.135723. Epub 2010 Oct 18.
17. Lin HK, Lan JL, Chen DY, Chen YH, Huang WN, Hsieh TY, et.al. The diagnostic value of anti cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Formosan J Rheumatol. 2008; 22:68-73.
18. Yildirim K, Karatay S, Melikoglu MA, et al. Associations between acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid arthritis. Ann Clin Lab Sci. 2004 Autumn;34(4):423-6.
19. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis. 2004;63(9): 1085-9.DOI:10.1136/ard.2003.016808
20. Aotsuka S, Okawa-Takatsuji M, Nagatani K, Nagashio C, Kano T, Nakajima K, et al. A retrospective study of the fluctuation in serum levels of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2005; 23(4):475-81.
OAI - Open Archives Initiative
